This experiment addresses AD Knowledge Gap #1 (33 points, Critical): "Why does amyloid removal only slow decline 27%?"[@sims2023][@van2023] Lecanemab and donanemab achieve dramatic amyloid clearance (CENTIRON: 60-80% reduction in amyloid plaques) yet clinical benefits are modest (~27% slowing of decline over 18 months). This paradox suggests that either: (1) amyloid is not the primary driver of neurodegeneration, (2) irreversible damage occurs before treatment initiation, or (3) off-target effects or mechanism limitations reduce efficacy. Understanding this is essential for next-generation AD therapeutic development.
The limited clinical benefit from amyloid removal is due to: (1) Tau-mediated neurodegeneration dominates — amyloid reduction does not halt tau-driven synaptic loss already underway; (2) Treatment timing too late — by the time patients have detectable amyloid, significant tau pathology and synaptic loss has already occurred; (3) Incomplete plaque clearance — residual oligomeric species continue to propagate pathology; (4) Neuroinflammation as independent driver — microglial activation continues despite amyloid removal.
Data sources: Pooled data from lecanemab (CLARITY, AHEAD), donanemab (TRAILBLAZER-ALZ 2), and other anti-amyloid trials
Analysis:
Key questions:
Model systems:
Endpoints:
Design: Retrospective modeling of "what if" earlier intervention
Analysis:
Deliverable: Decision framework for anti-amyloid therapy candidacy based on biomarker profile
| Dimension | Score | Rationale |
|---|---|---|
| Technical | 9/10 | Existing data and assays; requires data sharing agreements |
| Timeline | 8/10 | 36 months; retrospective phase faster |
| Cost | 8/10 | Estimated $3.5M; leverages existing trial infrastructure |
| Interpretability | 8/10 | Clear clinical endpoints; multiple mechanistic readouts |
| Phase | Cost |
|---|---|
| Phase 1 (Data Analysis) | $1.0M |
| Phase 2 (Mechanism) | $1.2M |
| Phase 3 (Modeling) | $1.3M |
| Total | $3.5M |